期刊
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
卷 15, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/17588359231160140
关键词
gp100; ImmTAC; metastatic; tebentafusp; uveal melanoma
类别
Tebentafusp is a novel immunotherapy agent that targets specific cells and has shown efficacy in treating advanced solid cancer and uveal melanoma. It is the first bispecific T-cell engager to demonstrate overall survival benefit and offers new possibilities for the management of advanced UM.
Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). This review article will focus on the clinical development of tebentafusp, the mechanism of action and resultant evolution of the management of advanced UM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据